Cimerli isn't the first biosimilar of Lucentis (ranibizumab ... It has a list price of $1,130 per single-use vial. Coherus, meanwhile, says it plans to launch Cimerli in October, with those ...

At the time, Opthea said it would consider the impact on the phase 3 Shore trial—which has been assessing sozinibercept in combination with Novartis’ Lucentis and was due to read out this year.

Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz. Byooviz (ranibizumab ...